Omeros Corporation

NASDAQ:OMER

Biotechnology

Healthcare
$14.55 +4.46%

+$0.43 today

Market cap
$1.08B
Beta
2.53
P/E (TTM)
8.4
EPS (TTM)
$1.20
52W Low $2.95High $17.65

Volume 2.53M

Average 1.55M

OMER Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Omeros CorporationNASDAQ: OMER

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 55.3% from a year ago

Cash & equivalents stood at $1.91M at the end of Q1 FY2026, down 55.3% from a year earlier and down 80.3% from the prior quarter. Over 3 fiscal years it compounded at -4.3% a year.

Context

  • Cash & equivalents amounted to 0.7% of total assets at the end of Q1 FY2026, down 1.1 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -55.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.91M-80.3% QoQ
Last fiscal yearDec 2025
$9.66M+184.1% YoY
Year agoMar 2025
$4.26M-55.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-55.3%——
1 year+184.1%——
3-year CAGR-4.3%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
9.66M USD
Year-over-year change
+184.1%
4-year CAGR
-44.4%

Cash & Equivalents vs competitors

How OMER compares with its peers on the latest reported figures

  • OMER's Mar 2026 cash & equivalents of $1.91M is the lowest of the 11 companies compared; the peer median is $55.59M.
  • Its year-over-year change of -55.3% is the lowest of 11, against a peer median of -5.5%.
  • Cash & equivalents amounts to 0.7% of total assets for OMER, versus a peer median of 17.4%.
OMER Competitors Peer median
Cash & Equivalents for OMER and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANABAnaptysBio, Inc.Mar 2026$248.47M +151.9%+49.5%75.4%
BHVNBiohaven Ltd.Jun 2026$238.03M +43.6%+3.9%64.2%
RCUSArcus Biosciences, Inc.Jun 2026$150M -39.5%+2.5%16.2%
CGEMCullinan Therapeutics, Inc.Mar 2026$75.08M -2.1%-17.3%18.6%
MGNXMacroGenics, Inc.Mar 2026$66.52M -54.3%-19.3%30.5%
XNCRXencor, Inc.Jun 2026$44.66M +0.5%+0.1%6.2%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$40.1M +702.2%-29.7%15.8%
NKTRNektar TherapeuticsJun 2026$39.11M -9.0%-44.5%3.6%
MREOMereo BioPharma Group plcMar 2026$36.22M -42.0%-15.6%89.2%
CGENCompugen Ltd.Mar 2026$12.44M -14.7%+101.6%8.5%
OMEROmeros CorporationMar 2026$1.91M -55.3%-4.3%0.7%
Peer median (excluding OMER) $55.59M-5.5%-7.8%17.4%

Competitors are the stored peer set for OMER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents100.81M11.01M7.11M3.4M9.66M
Short-term Investments56.46M183.91M164.74M86.73M162.14M
Net Receivables82.47M242.02M6.72M36.82M36.27M
Inventory00000
Other Current Assets67K6.3M30.75M7.17M7.6M
Total Current Assets247.96M443.24M217.9M134.12M215.67M
Property, Plant & Equipment (Net)30.01M23.25M20.58M17.64M12.48M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets141.31M124.48M139.79M125.32M97.49M
Total Non-current Assets171.31M147.73M160.37M142.96M109.97M
Total Assets419.27M590.97M378.27M277.08M325.63M
Account Payables13.4M5.99M7.71M5.91M4.76M
Short-term Debt094.38M8.58M21M17.06M
Tax Payables338K4.87M000
Deferred Revenue00002.47M
Other Current Liabilities3.71M7.82M029.51M30.9M
Total Current Liabilities51.79M136.38M53.32M79.53M78.06M
Long-term Debt313.46M220.91M329.71M166.58M208.54M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.12M125.57M2.09M200.11M153.02M
Total Non-current Liabilities343.7M368.9M349.94M380.16M368.8M
Total Liabilities395.49M505.29M403.25M459.69M446.86M
Common Stock626K628K611K580K716K
Retained Earnings(683.13M)(635.72M)(753.53M)(910.35M)(913.7M)
Accumulated OCI00(0)00
Other Stockholders Equity00000
Minority Interest00000
Total Equity23.78M85.68M(24.98M)(182.61M)(121.23M)
Total Debt347.84M342.02M361.58M207.02M239.14M
Net Debt247.03M331.01M354.48M203.62M229.48M

Omeros Corporation

NASDAQ:OMER

Intrinsic Alpha fair value

Locked

Current Price

$14.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.